Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Research

• Publication date

  2003-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 14679010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The genotoxicity of tamoxifen: extent and consequences, Kona, Hawaii, January 23, 2003.

  2003cited by this paper
• Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry.

  2003cited by this paper
• Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans.

  2003cited by this paper
• Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria.

  2003cited by this paper
• Effect of Selective Estrogen Receptor Modulators on Reproductive Tissues Other Than Endometrium

  2001cited by this paper
• Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat

  2001cited by this paper
• Human fertility and reproduction : the oocyte, the embryo, and the uterus

  2001cited by this paper
• Role of Exogenous and Endogenous Hormones in Endometrial Cancer

  2001cited by this paper
• Risk and Prognosis of Endometrial Cancer After Tamoxifen for Breast Cancer

  2001cited by this paper
• Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.

  2000cited by this paper
• Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research.

  2000cited by this paper
• Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement.

  2000cited by this paper
• Comparison of DNA‐adduct and tissue‐available dose levels of MeIQx in human and rodent colon following administration of a very low dose

  1999cited by this paper
• Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen.

  1999cited by this paper
• Species and strain comparisons in the macromolecular binding of extremely low doses of [14C]benzene in rodents, using accelerator mass spectrometry.

  1999cited by this paper
• Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts.

  1998cited by this paper
• Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen.

  1997cited by this paper
• Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry.

  1997cited by this paper
• Lack of genotoxicity of tamoxifen in human endometrium.

  1996cited by this paper
• Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.

  1996cited by this paper
• Age‐related difference in tamoxifen disposition

  1996cited by this paper
• Tamoxifen associated uterine pathology in rodents: relevance to women.

  1996cited by this paper
• Dose-response studies of MeIQx in rat liver and liver DNA at low doses.

  1995influential reference
• DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation.

  1995influential reference
• Accelerator mass spectrometry.

  1995cited by this paper
• IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

  1995cited by this paper
• Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats.

  1993cited by this paper
• Studies on DNA adduction with heterocyclic amines by accelerator mass spectrometry: a new technique for tracing isotope-labelled DNA adduction.

  1993cited by this paper
• The case for clinical trials of tamoxifen for prevention of breast cancer.

  1992cited by this paper
• Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation.

  1991cited by this paper
• Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.

  1991cited by this paper
• Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA.

  1990cited by this paper
• Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers.

  1989cited by this paper
• Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.

  1980cited by this paper
• The Metabolism of Tamoxifen (I.C.I. 46,474) Part II: In Female Patients

  1973cited by this paper
• The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients.

  1973cited by this paper

• Radiolabeling, quality control, and in vitro cell culture studies of [99mTc]Tc-tamoxifen citrate for estrogen receptor-positive breast cancer imaging.

  2025cites this paper
• Oxidative DNA damage induced by 3,4-diOH-TAM, a tamoxifen metabolite, in relation to endometrial carcinogenesis

  2025cites this paper
• The New Anti-Estrogens with Anti-Cancer Properties for Breast Cancer

  2023cites this paper
• Investigation of the role of quercetin as a heat shock protein inhibitor on apoptosis in human breast cancer cells

  2020cites this paper
• Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science

  2019cites this paper
• Female Reproductive C: Uterine Tumors and the Environment

  2018cites this paper
• Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties

  2016cites this paper
• Uterine carcinosarcoma / mixed Müllerian tumor incidence is increased in women with breast cancer , but independent of hormone therapy

  2015cites this paper
• Uterine carcinosarcoma/malignant mixed Müllerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy

  2015influential citation
• An organizational approach for the assessment of DNA adduct data in risk assessment: case studies for aflatoxin B1, tamoxifen and vinyl chloride

  2014influential citation
• Biodegradable Guar Gum Nanoparticles as Carrier for Tamoxifen Citrate in Treatment of Breast Cancer

  2014cites this paper
• Tamoxifen-DNA adduct formation in monkey and human reproductive organs.

  2014cites this paper
• Effect of DNA repair deficiencies on the cytotoxicity of drugs used in cancer therapy - a review.

  2014cites this paper
• Peroxidase mediated dealkylation of Tamoxifen detected by ESI-MS and activation to form of DNA adducts

  2013cites this paper
• Microdosing and drug development: past, present and future

  2013cites this paper
• IN-VITRO CYTOTOXICITY ANALYSIS OF TAMOXIFEN CITRATE LOADED CROSS-LINKED GUAR GUM NANOPARTICLES ON JURKAT (HUMAN T-CELL LEUKEMIA) CELL LINE

  2012cites this paper
• Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts.

  2012cites this paper
• Methods for the detection of DNA adducts.

  2012cites this paper
• Montmorillonite/poly-(ε-caprolactone) composites as versatile layered material: reservoirs for anticancer drug and controlled release property.

  2012cites this paper
• Measurement of oxidatively generated base damage to nucleic acids in cells: facts and artifacts

  2012cites this paper
• Development of accelerator mass spectrometer based on a compact cyclotron

  2011cites this paper
• Quantitative Drug Metabolism with Accelerator Mass Spectrometry

  2011cites this paper
• Synthesis of a radioiodinated antiestrogen glucuronide compound (TAM-G)

  2011cites this paper
• Anti‐breast cancer potential of SS5020, a novel benzopyran antiestrogen

  2011influential citation
• Accelerator mass spectrometry-enabled studies: current status and future prospects.

  2010cites this paper
• Anti‐breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions

  2010influential citation
• Accelerator mass spectrometry best practices for accuracy and precision in bioanalytical (14)C measurements.

  2010cites this paper
• Carcinosarcoma arising in uterine didelphys after tamoxifen therapy for breast cancer: a case report.

  2010cites this paper
• Investigations into the expression of sirtuins in breast cancer: in vivo and in vitro studies

  2010cites this paper
• Uterine Tumors and the Environment

  2010cites this paper
• Is tamoxifen a genotoxic carcinogen in women?

  2009cites this paper
• Differences in metabolite-mediated toxicity of tamoxifen in rodents versus humans elucidated with DNA/microsome electro-optical arrays and nanoreactors.

  2009cites this paper
• Creating context for the use of DNA adduct data in cancer risk assessment: II. Overview of methods of identification and quantitation of DNA damage

  2009cites this paper
• [Uterine sarcoma associated with tamoxifen use after breast cancer: Review of the pathogenesis].

  2009cites this paper
• Sarcomes utérins après exposition au tamoxifène dans les suites d ’ un cancer du sein : mise au point sur l ’ étiopathogénie Uterine sarcoma associated with tamoxifen use after breast cancer : Review of the pathogenesis

  2009cites this paper
• Tamoxifen induces expression of immune response-related genes in cultured normal human mammary epithelial cells.

  2009cites this paper
• Pharmaceutical Applications of Accelerator Mass Spectrometry

  2009cites this paper
• Recent advances in biomedical applications of accelerator mass spectrometry

  2009cites this paper
• Study on N-Nitrosoureas by Electron Spray Ionization Mass Spectrometry

  2008cites this paper
• 131I labeling of tamoxifen and biodistribution studies in rats.

  2008cites this paper
• Tumorigenic Effects of Tamoxifen on the Female Genital Tract

  2008cites this paper
• Application of mode-of-action considerations in human cancer risk assessment.

  2008cites this paper
• Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots

  2008cites this paper
• Assessing the mammary gland of nonhuman primates: effects of endogenous hormones and exogenous hormonal agents and growth factors.

  2007cites this paper
• Tamoxifen: important considerations of a multi-functional compound with organ-specific properties.

  2007cites this paper
• The DNA-damaging potential of tamoxifen in breast cancer and normal cells

  2007cites this paper
• Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose.

  2007cites this paper
• Effect of N,N-didesmethyltamoxifen upon DNA adduct formation by tamoxifen and α-hydroxytamoxifen

  2007cites this paper
• The supF assay for understanding DNA adduct-induced mutagenesis : traditional application and development of a site-specific version

  2007cites this paper
• Effect of N,N-didesmethyltamoxifen upon DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen.

  2007cites this paper
• Antiestrogens and the formation of DNA damage in rats: a comparison.

  2006cites this paper
• Translesion synthesis past tamoxifen-derived DNA adducts by human DNA polymerases eta and kappa.

  2006cites this paper
• Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.

  2006cites this paper
• Applications of accelerator mass spectrometry for pharmacological and toxicological research.

  2006cites this paper
• The effects of selective oestrogen receptor modulators in the uterus

  2006cites this paper
• INEFFICIENT REPAIR OF TAMOXIFEN-DNA ADDUCTS IN RATS AND MICE

  2006cites this paper
• Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance

  2006cites this paper
• Is tamoxifen a genotoxic carcinogen in women

  2006cites this paper
• ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006.

  2006cites this paper
• ECNIS-sponsored workshop on biomarkers of exposure and cancer risk : DNA damage and DNA adduct detection and 6 th GUM-32 P-postlabelling workshop

  2006cites this paper
• Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells.

  2005cites this paper
• Mutation spectra induced by alpha-acetoxytamoxifen-DNA adducts in human DNA repair proficient and deficient (xeroderma pigmentosum complementation group A) cells.

  2005cites this paper
• Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods.

  2005cites this paper
• 14) Accelerator Mass Spectrometry for Biomedical Research

  2005cites this paper
• Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.

  2005cites this paper
• Organ specificity of DNA adduct formation by tamoxifen and a -hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment

  2005cites this paper
• Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives.

  2005cites this paper
• FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF α-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS

  2005cites this paper
• DNA adducts: mass spectrometry methods and future prospects.

  2005cites this paper
• A deoxynucleotide derivatization methodology for improving LC-ESI-MS detection.

  2005cites this paper
• Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.

  2005cites this paper
• Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.

  2005cites this paper
• Stereoselective metabolic activation of alpha-hydroxy-N-desmethyltamoxifen: the R-isomer forms more DNA adducts in rat liver cells.

  2004cites this paper
• Genotoxic Mechanism of Tamoxifen in Developing Endometrial Cancer

  2004influential citation
• Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling.

  2004cites this paper
• Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases

  2004cites this paper
• Techniques: the application of accelerator mass spectrometry to pharmacology and toxicology.

  2004cites this paper
• Current literature in mass spectrometry.

  2004cites this paper
• Translesion Synthesis past Tamoxifen-derived DNA Adducts by Human DNA Polymerases η and κ

  2004cites this paper
• Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans.

  2004cites this paper
• Accelerator mass spectrometry for biomedical research.

  1993cites this paper